Nitradisc

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitradisc

Property Description
Active Ingredient Nitroglycerin (Glyceryl trinitrate)
Form Transdermal Patch (TTS)
Pharmacological Class Organic Nitrate, Vasodilator
General Purpose To reduce cardiac workload and maintain circulatory stability
Origin Synthetic

Nitradisc: Definition and Pharmacological Class

Nitradisc is the trade designation for a prescription-only medicine that utilizes the active chemical substance Nitroglycerin, known chemically as Glyceryl trinitrate (GTN). It is classified within the pharmacological group of Organic Nitrates and operates as a vasodilator, a mechanism clinically recognized for its role in modifying vascular resistance. The drug is a synthetic, single-active ingredient product, distinct from combination therapies. Its core identity as a vasodilator establishes its fundamental function: acting directly on the vascular system to promote relaxation and widening of blood vessels.

What is the Transdermal Therapeutic System (TTS) Form?

The unique pharmaceutical preparation of this medication is the transdermal patch, technically defined as a Transdermal Therapeutic System (TTS). This specialized dosage form is designed for topical (transdermal) administration, enabling the controlled delivery of Nitroglycerin across the skin and into the bloodstream. Unlike the rapid action of sublingual tablets, the patch's structure involves the active ingredient being embedded within an adhesive matrix, which facilitates a continuous, sustained release of the medication over a prolonged duration. This sustained release profile is critical for ensuring a steady therapeutic effect.

General Purpose and Core Physiological Effect

The general purpose of this medication is to support cardiac efficiency by promoting a favorable balance between the heart’s oxygen demand and its available supply. This is accomplished because the Nitroglycerin substance is metabolized into nitric oxide, a signaling molecule that directly triggers the relaxation of vascular smooth muscle. By promoting widespread vasodilation, the medication effectively decreases the amount of blood returning to the heart, which directly lessens the heart's overall workload. This core physiological effect ensures that the circulatory demands are minimized, constituting the foundation for the product's function as a prophylactic agent in long-term circulatory support.

Regulatory References

  1. NCBI Bookshelf - NIH

What side effects are possible with Nitradisc?

Possible Side Effects and Safety Information

The safety profile for the Nitroglycerin transdermal system is structured around adverse reactions that result primarily from its intended effect as a potent vasodilator. All listed reactions and safety constraints are documented in official government regulatory documents.

Frequency-Classified Adverse Reactions

The adverse reactions are categorized by the frequency observed in clinical data, following regulatory standards:

  • Very Common (10% or more): Headache is the most frequently reported effect, which may occur with each daily dose but often decreases in severity with continued therapy.
  • Common (1% to 10%): Dizziness, somnolence (drowsiness), orthostatic hypotension (low blood pressure upon standing), tachycardia (increased heart rate), nausea, and vomiting.
  • Uncommon (0.1% to 1%): Allergic skin reactions, including rash and allergic contact dermatitis, as well as application site reactions such as erythema (redness), pruritus (itching), and burning.

System-Organ Classes and Serious Events

The documented adverse reactions affect systems including Nervous System, Vascular, Cardiac, Gastrointestinal, and Skin/Subcutaneous Tissue.

Serious adverse reactions documented in regulatory sources include severe hypotension and circulatory collapse, sometimes accompanied by syncope (fainting). Enhanced angina pectoris symptoms have been observed in some patients during the necessary nitrate-free interval of intermittent therapy.

Safety Constraints and Population Notes

The medication is contraindicated for use with certain other potent vasodilating agents, such as Phosphodiesterase-5 (PDE-5) Inhibitors, due to the established risk of profound hypotension. Additional safety restrictions apply to individuals with marked anemia, acute circulatory failure, severe hypotension, or conditions causing elevated intracranial pressure.

Population-specific safety notes include caution for older adults, who may be more susceptible to hypotension and an increased risk of falling, as well as for patients with severe anemia or hypovolemia.

Overdose and Emergency Response

Overdose Manifestations and When to Seek Help

An overdose of Nitradisc is officially defined by severe manifestations primarily resulting from massive vasodilation. Documented clinical presentations listed in regulatory sources include a severe and persistent throbbing headache, profound hypotension (low blood pressure), confusion, vertigo, and fainting (syncope). Systemic signs may involve flushing, excessive sweating, and gastrointestinal symptoms such as nausea, vomiting, and bloody diarrhea.

Severe outcomes listed in official documents include cardiovascular collapse, seizures, and coma, with death being a possibility. Methemoglobinemia is also noted as a potential consequence of severe exposure.


Regulatory-Mandated Emergency Actions

When an overdose is suspected, immediate action is mandatory: the transdermal patch must be removed. Patients exhibiting critical signs such as collapse, difficulty breathing, seizures, or an inability to be awakened require that emergency services be contacted immediately.

According to official labeling, no specific antagonist (antidote) is known to reverse the effects. Management focuses on supportive measures, such as passively elevating the patient's legs and administering intravenous fluids to restore central fluid volume. The use of epinephrine or other arterial vasoconstrictors is advised against. Treatment is noted as particularly complex in patients with renal disease or congestive heart failure.

Therapeutic Uses of Nitradisc

Quick Facts

  • Primary Therapeutic Use: Prevention of chest discomfort (angina pectoris).
  • Condition Addressed: Angina related to coronary artery disease.
  • Therapeutic Goal: To reduce the occurrence of anginal episodes.

What Nitradisc Treats: Main Uses and Benefits

Nitradisc is a prescribed transdermal system indicated for the management of stable angina pectoris. It is specifically used to support the prevention of anginal chest discomfort that results from coronary artery disease (CAD). The medication works to reduce the frequency of these episodes over time by affecting the circulatory system, which may ease the demands placed on the heart.

This transdermal form of the medication offers a method for continuous delivery, contributing to a maintained therapeutic level to assist in prophylaxis. It is important to note that this product is formulated for the long-term management and prevention of angina and is not to be used for the immediate relief of an acute anginal attack once it has begun. Patients experiencing an acute attack should seek guidance on suitable fast-acting options.

The use of this system may be incorporated into a comprehensive treatment plan to manage the patient's condition.

Regulatory References

  1. NIH MedlinePlus guidance on Nitroglycerin

Eligibility and Restrictions for Use

Who Can and Cannot Use Nitradisc? (Official Regulatory Information)

Official regulatory documents define specific populations and conditions that strictly govern the eligibility for using the Nitradisc (nitroglycerin transdermal system).

Contraindications (Must Not Use)

Use is strictly contraindicated for individuals meeting any of the following criteria:

  • Known hypersensitivity or allergy to nitroglycerin, other organic nitrates or nitrites, or any component (including adhesives) of the transdermal system.
  • Concurrent use of phosphodiesterase type 5 (PDE-5) inhibitors (such as sildenafil, vardenafil, or tadalafil) or the soluble guanylate cyclase (sGC) stimulator riociguat.
  • Specific acute or severe clinical states, including severe anemia, conditions causing increased intracranial pressure (e.g., cerebral hemorrhage or head trauma), acute circulatory failure or shock, or myocardial insufficiency due to obstruction (e.g., aortic or mitral stenosis).

Special Considerations and Restrictions

The safety and efficacy of Nitradisc have not been established for use in pediatric patients (under 18 years of age).

Use requires caution in patients who are hypotensive or volume-depleted, and in those with hypertrophic cardiomyopathy. Older adult patients may be more susceptible to hypotension with treatment. The product is not intended for the relief of an acute attack.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Nitradisc (Nitroglycerin transdermal system) is primarily defined by the risk of severe hypotension when co-administered with other vasodilators.

Contraindicated Combinations

The use of Nitradisc is strictly prohibited with certain medications due to the potential for severe, life-threatening drops in blood pressure and circulatory collapse. These agents include Phosphodiesterase type 5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat).

Documented Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with other antihypertensive agents or alcohol (ethanol) may result in additive vasodilating effects, leading to an increased risk of hypotension. Regulatory documents advise caution with this combination. Conversely, the co-administration of Ergotamine and related drugs may antagonize the vasodilatory effect of Nitroglycerin.

The medication also has exposure-altering effects on other drugs. The concurrent use of Nitroglycerin may increase the oral bioavailability of Dihydroergotamine due to reduced first-pass metabolism. Additionally, its use may reduce the anticoagulant effect of Heparin and decrease the thrombolytic effect of Alteplase.

Official labeling notes that elderly patients may be more susceptible to severe hypotension, especially when they are already on multiple medications or are volume-depleted.

Mechanism of Action

How Nitradisc Works: Mechanism of Action

Nitradisc's mechanism is initiated by its function as a pro-drug. The active ingredient, Nitroglycerin, requires intracellular enzymatic conversion within the vascular smooth muscle cells, carried out primarily by the enzyme Mitochondrial Aldehyde Dehydrogenase 2 (ALDH2). This bioactivation generates Nitric Oxide (NO), an endogenous signaling molecule.

NO rapidly activates soluble Guanylate Cyclase (sGC), which synthesizes the second messenger cyclic Guanosine Monophosphate (cGMP). Elevated cGMP activates protein kinase G (PKG), initiating the dephosphorylation of myosin light chains. This process results in the relaxation and widening of blood vessels (vasodilation).

This widespread vasodilation predominantly affects the large peripheral veins (capacitance vessels), which results in blood pooling. The pooling reduces the volume of blood returning to the heart (preload). By reducing this returning volume and, to a lesser extent, reducing the resistance the heart pumps against (afterload), this mechanism leads to a reduction in the physical effort and workload placed upon the cardiac muscle.

The mechanism is subject to constraint: continuous exposure can functionally impair the ALDH2 enzyme, which weakens the biological pathway's ability to generate sufficient NO, leading to the condition known as nitrate tolerance.

Dosage and Administration Information

How to Use Nitradisc: Official Administration Guidelines

The correct use of the Nitradisc (nitroglycerin) transdermal system is defined by official instructions to ensure proper delivery and maintain therapeutic efficacy. This medication is strictly for the prophylactic (preventive) management of angina and is not to be used for the immediate relief of an acute anginal episode.

Administration and Dosage Principles

Detail Official Administration Instruction
Route of Administration Transdermal (Topical application to intact skin).
Dosage Form and Strengths Transdermal patches available in multiple strengths, typically releasing nitroglycerin at continuous rates such as 0.1 mg/hour to 0.6 mg/hour.
Starting Dose Dosing generally begins at the lowest strength, often 0.2 mg/hour or 0.4 mg/hour, adjusted based on patient needs.

The Cyclic Dosing Schedule

The transdermal patch must be administered using a cyclic regimen to prevent the development of tolerance, a condition where the body loses its responsiveness to the drug. This schedule is non-continuous and requires the following pattern:

  • Wear Period (Patch-On): The patch is applied once daily and worn for a defined period, typically 12 to 14 hours.
  • Nitrate-Free Period (Patch-Off): The patch must be removed daily for an interval of 10 to 12 hours before applying a new patch.

Application Instructions

For proper use, the patch should be applied to a clean, dry, and hairless area of the skin, typically on the upper body, such as the upper arm or chest. It is essential to rotate the application site daily to prevent localized skin irritation.

Restrictions and Special Populations

Do not cut, trim, or alter the patch, as this can disrupt the controlled-release mechanism. For older adults, dose selection should be approached with caution, often starting at the low end of the dosing range.

Recent Clinical Evidence

Nitradisc: Overview of Clinical Evidence

This section summarizes the type of formal clinical research that has been conducted on Nitradisc (nitroglycerin transdermal system). The findings described here reflect group patterns observed in clinical trials and research provides context but not individual predictions. The evidence helps contextualize what was studied for its approved use.


Evidence for Use in Chronic Stable Angina Pectoris (Prevention)

The clinical research exploring the nitroglycerin patch for the prevention of chest discomfort (angina pectoris) includes short-term, randomized controlled trials (RCTs). These studies included double-blind and placebo-controlled designs, and primarily examined the product in adult subjects with stable angina, a condition characterized by fluctuating or episodic manifestations of chest discomfort related to coronary artery disease.

  • How Efficacy Was Measured in Trials

    The studies primarily monitored outcomes related to functional imbalance and physical discomfort. The main outcomes evaluated in these trials focused on subjects' physical capacity during controlled exercise testing. Researchers recorded measurements of the time subjects could walk on a treadmill before they developed anginal pain. They also explored physiological signs, such as the time it took for certain changes (ST-segment depression) to appear on the ECG, which are considered outcomes monitoring physiological strain or stress. Additionally, studies applied in research exploring patient-reported experiences by tracking the frequency of anginal episodes and how often subjects used fast-acting rescue medications.

Studies monitored measurements taken several hours after patch application in intermittent dosing protocols and reported how outcomes evolved in the areas of exercise time to angina onset and ST-segment depression in some trial groups. These patterns contribute to the broader evidence landscape used to characterize the medicine's role in prevention.


Durability of Effect and the Challenge of Tolerance

Research explored how the measurements taken after patch application were observed in studies over extended wear periods. This line of research helped contextualize findings related to pharmacological tolerance, a key limitation of the transdermal delivery system.

Trial reports describes patterns observed in the studies where the measured effect often diminished or was lost when the patch was applied in a continuous, 24-hour regimen. The continuous presence of the medicine was associated with outcomes becoming similar to those of the placebo group after a period of time. The research describes patterns that led to the investigation of protocols where the patch is worn for a defined period (e.g., 12 to 14 hours) and then removed for a patch-free interval (e.g., 10 to 12 hours).

Long-Term Studies and Extended Follow-Up

The majority of the research contributes to the broader evidence landscape by focusing on short-term symptom patterns, with the duration of the key trials generally ranging from only two to four weeks.

Long-term effects are not fully established. The follow-up durations were limited in these studies, meaning there is limited information for long-term outcomes that may extend over many months or years. Research provides insight into short-term changes in physical function but does not fully characterize the outcomes reflecting daily functioning or activity level over periods longer than the study durations.

Evidence in Specific Patient Populations

The available evidence is primarily derived from research exploring short-term symptom changes in adult populations with confirmed chronic stable angina and coronary artery disease.

Data for certain groups remain insufficient. Sample sizes were modest in some early trials, and the results apply only to the populations studied. There is limited information from large, dedicated studies evaluating outcomes in certain subgroups, such as older adults, children, or populations with specific co-existing conditions. Subgroup findings are an area where certainty remains low compared to the core adult patient population.

What is Still Uncertain About Nitradisc Research

This synthesis highlights areas where certainty remains low or where the evidence is limited regarding the complete clinical picture of the transdermal system.

One key finding of uncertainty was observed in some studies that explored the potential for a temporary decrease in physical tolerance or an increase in the number of anginal episodes during the required patch-free interval. While these findings were not universally reported, they contribute to the broader evidence landscape that requires further clarification. Overall, while efficacy was observed in trials using intermittent dosing, comparative evidence is lacking for many potential subgroups, and research is ongoing in this therapeutic area. Evidence highlights what is known — and what is still uncertain.

Key Studies & References Nitroglycerin Transdermal Patch: MedlinePlus Drug Information (General Patient and Indication Context)

Frequently Asked Questions (FAQ)

Common questions about Nitradisc (FAQ)

Q: Is Nitradisc the same as nitroglycerin pills?

A: Nitradisc is a transdermal patch designed for sustained delivery of the active ingredient, nitroglycerin, across the skin. Official documents indicate this form is used for the prevention of chest discomfort. This differs from other forms, such as sublingual (under-the-tongue) nitroglycerin pills, which are designed for rapid, immediate action to relieve acute episodes.

Q: How long does it take for the Nitradisc patch to start working?

A: Official pharmacokinetic data indicate that when the patch is applied, the medication begins to be absorbed. The sustained therapeutic concentration in the bloodstream, known as a steady-state plasma level, is typically reached about two hours after applying the patch.

Q: Can I shower or swim while wearing the Nitradisc patch?

A: Official instructions advise applying the patch to clean, dry, and intact skin to ensure proper adhesion and drug delivery. The patches are generally designed to stay on during normal daily activities, including showering. However, prolonged water exposure, such as swimming, may affect the patch's adhesion, potentially compromising its sustained-release function.

Q: What happens if I forget to change the Nitradisc patch at the right time?

A: Official instructions advise that if a dose is missed, the patch may be applied as soon as it is remembered to maintain the proper schedule. If it is almost time for the next scheduled patch, the missed one should be skipped. It is important never to apply two patches at once to make up for a missed dose.

Q: Where is the best place on the body to apply the Nitradisc patch?

A: Regulatory instructions state that the patch should be applied to a clean, dry, and hairless area of the skin to ensure proper adhesion. Commonly cited areas in official documents include the upper arm or the chest. The application site should be rotated daily to prevent skin irritation.

Q: Can women who are pregnant or breastfeeding use Nitradisc?

A: Official product information indicates that there are no adequate and well-controlled studies specifically examining the effects of the transdermal system in pregnant women. Similarly, official documents contain no data on whether the medication is present in human milk during breastfeeding. Therefore, the use of this medication during pregnancy or breastfeeding requires caution.

Q: Is Nitradisc suitable for older adults?

A: Official regulatory labels advise that dose selection for older adult patients should be approached with caution. This population may be more susceptible to effects such as hypotension (low blood pressure), and the official guidance often suggests starting treatment at the low end of the dosing range.

Q: Are there any foods or drinks I need to avoid while using Nitradisc?

A: Official regulatory sources specifically mention the risk of interaction with alcohol (ethanol) due to the potential for additive blood-pressure-lowering effects. However, no specific contraindications or warnings are listed regarding the consumption of typical solid foods or non-alcoholic drinks.

Q: Is it common to feel dizzy or lightheaded after applying Nitradisc?

A: Yes, regulatory documents list both dizziness and orthostatic hypotension (a drop in blood pressure when changing position that causes lightheadedness or fainting) as Common side effects. These effects result from the medication's intended function as a blood vessel dilator.

Q: What is the risk of developing a tolerance to Nitradisc over time?

A: The risk of developing tolerance (where the body loses responsiveness to the drug) is a known pharmacological characteristic of continuous nitrate delivery. To prevent this, the official regulatory documents mandate a required daily patch-free interval (typically 10 to 12 hours) to restore drug sensitivity.

Q: Can Nitradisc be used for chest discomfort that is not related to a heart condition?

A: No. The approved indication in regulatory documents is strictly for the prophylactic management of angina pectoris (chest discomfort) that is due to coronary artery disease. It is not approved for use in other types of chest discomfort.

Q: Why do official documents mention 'patch-free' intervals for Nitradisc?

A: Official documents specify the daily patch-free period to prevent the development of pharmacological tolerance. This interval breaks the continuous exposure to the medication, which is necessary to maintain the drug's effectiveness over time.

Q: Can I use a heating pad or electric blanket near the patch site?

A: Official patient information often advises against exposing the application site to sources of excessive heat, such as heating pads, electric blankets, or prolonged direct sun exposure. Heat can potentially increase the rate at which the medication is absorbed through the skin, leading to a possible increase in systemic effects.

Q: Is Nitradisc commonly prescribed in other countries, and for what?

A: The active ingredient in transdermal patch form, nitroglycerin (glyceryl trinitrate), is approved and commonly used internationally by regulatory bodies across various countries. It is used worldwide for the same approved indication: the prophylactic (preventive) treatment of angina pectoris.

Q: How long does the medication stay in my system after removing the Nitradisc patch?

A: While the active substance, nitroglycerin, has a very short half-life (a few minutes), the subsequent metabolism of the drug creates active metabolites. Official pharmacokinetic data indicates that these metabolites have a longer half-life, meaning the substance and its products remain in the body for some time after the patch is removed.

Q: Can Nitradisc be used by people with a history of severe migraines?

A: Official regulatory labels list headache as a Very Common side effect of the medication. While severe migraine itself is not listed as a specific contraindication, caution is generally advised for use with conditions that cause increased intracranial pressure, which can sometimes be a factor in severe headaches.

Q: Is Nitradisc a common treatment for the described conditions?

A: Official regulatory documents confirm that the product is a prescription-only medicine that has been evaluated through controlled clinical trials for its approved indication. This confirms its established role as a treatment option within the regulated pharmaceutical landscape for the prevention of angina pectoris.

Q: What should I do if I accidentally apply two Nitradisc patches at once?

A: Official patient information advises that in the event of using more than the prescribed amount, such as applying two patches, the patient should seek immediate medical attention. Applying extra patches can result in an overdose, potentially leading to severe hypotension (extremely low blood pressure).

Q: Are there other transdermal patches similar to Nitradisc?

A: Yes. Regulatory documents classify Nitradisc within the pharmacological group of Organic Nitrates and Vasodilators. Other medications within this same pharmacological class and which utilize the transdermal (patch) delivery format exist and are referenced in broader official drug information.

Q: Does sun exposure affect how Nitradisc works?

A: Official patient information advises patients to avoid exposing the patch site to excessive heat or prolonged direct sunlight. Excessive heat can increase the rate of drug absorption through the skin, potentially leading to increased systemic effects of the medication.

Q: What is the difference between Nitradisc and oral nitrate medications?

A: Nitradisc is a transdermal patch that provides a sustained-release, continuous delivery over the wear period for prevention. In contrast, oral nitrate medications can be fast-acting sublingual tablets (for acute relief) or extended-release tablets/capsules (for prevention), meaning they differ in onset, duration, and administration method.

Q: Is the medication level constant throughout the wear time of the patch?

A: Official pharmacokinetic studies indicate that once the patch is applied, the medication level in the blood typically rises for a period until it reaches a steady-state concentration. This concentration is then generally maintained for the duration the system is worn, providing a sustained release.

Q: Are there any age limits for using the Nitradisc patch?

A: Official regulatory documents explicitly state that the safety and efficacy of the transdermal system have not been established for use in pediatric patients (those under 18 years of age).

Q: What should be avoided when applying the patch to ensure it sticks properly?

A: Official application instructions require the patch site to be clean, dry, and hairless. Patients are generally advised to avoid applying skin preparations like oils, lotions, or creams to the application site, as these can interfere with the patch's adhesion and proper drug absorption.

Q: Can Nitradisc interact with herbal supplements?

A: While specific herbal supplements may not be individually listed in official documents, regulatory guidance advises caution with all co-administered substances. Patient information often includes a general caution to inform a healthcare provider about all medicines and supplements, including herbal and over-the-counter products.

Q: Does Nitradisc have a risk of withdrawal symptoms when stopped?

A: Official regulatory documents note that enhanced angina symptoms have been observed in some patients during the necessary daily nitrate-free interval. Official documents often advise against abruptly stopping the medication, as some conditions may worsen.

Q: Can Nitradisc be used with blood pressure medicines?

A: Official documents state that using the transdermal system with other antihypertensive (blood pressure) agents may result in additive vasodilating effects. This combination may lead to an increased risk of hypotension (low blood pressure), and caution is advised.

Q: Can I put the patch on hairy areas, or must it be clean-shaven?

A: Official application instructions state the patch should be applied to a hairless area of the skin to ensure proper contact and absorption. If a hairless area is not available, the site should be prepared by clipping the hair; however, official application instructions often advise against shaving as it can irritate the skin.

Q: Can Nitradisc cause headaches, and if so, how long do they last?

A: Headache is listed as a Very Common side effect, often resulting from the dilation of blood vessels. Regulatory sources note that in clinical data, the severity often decreases with continued therapy, though the exact duration for every patient is not specified.

Q: Is it safe to drive or operate machinery while using Nitradisc?

A: Official documents list side effects like dizziness and somnolence (drowsiness) as Common. Regulatory guidance states that due to the potential for these side effects, caution should be exercised when driving or operating machinery until the patient understands how the medication affects them and if these effects occur.

Q: What should I tell my dentist or surgeon before a procedure if I'm using Nitradisc?

A: Official guidelines indicate that the patient's doctors, dentists, or surgeons should be informed they are using the transdermal system. This is crucial due to the risk of severe hypotension and potential interactions with certain medications used during procedures, such as Heparin.

Q: What are the differences in use conditions for the high-strength vs. low-strength Nitradisc?

A: Official documents indicate that while dosing generally begins at the lowest strength and is adjusted, the core use conditions—specifically the cyclic regimen and the required daily patch-free interval—are generally the same across all available strengths to prevent tolerance.

How should Nitradisc be stored and disposed of?

How to Store and Dispose of Nitradisc

Nitradisc (nitroglycerin) transdermal patches must be stored under specific environmental conditions to maintain stability and integrity. The product requires storage at Controlled Room Temperature (typically 20 C to 25 C) and must be protected from excess heat, direct light, and moisture. It is mandatory to keep the patches from freezing and to retain them in their original sealed pouch until the moment of application. The medicine must be stored out of the reach of children and pets.

Disposal requires specific handling: immediately after removal, the patch must be folded in half with the sticky sides pressed together to contain the residual drug. All used, unused, or expired patches must be discarded securely, following local regulatory disposal requirements or a community drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitradisc found in:

A-Z Index: